IHP 102
Alternative Names: IHP-102Latest Information Update: 18 Jan 2024
At a glance
- Originator IHP Therapeutics
- Class Antineoplastics
- Mechanism of Action Complement system protein inhibitors; P-selectin ligand protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute lung injury; Sickle cell anaemia; Solid tumours; Vaso-occlusive crisis
Most Recent Events
- 18 Jan 2024 Preclinical trials in Acute lung injury in USA (unspecified route) (IHP Therapeutics pipeline, January 2024)
- 18 Jan 2024 Preclinical trials in Solid tumours in USA (unspecified route) (IHP Therapeutics pipeline, January 2024)
- 09 Dec 2023 Preclinical trials in Sickle cell anaemia in USA (IV) prior to December 2023